Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery PlatformKey Takeaways Combined with its Seed round of $8.5M, the company has raised more than $16.5M in support of its activities. Vinci Pharmaceuticals closed an $8+ million Series A financing round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™...
- Cyrano TherapeuticsCyrano Therapeutics' Phase 2 FLAVOR Trial Selected to Open 72nd Annual Meeting of the American Rhinologic Society (ARS)Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders, today announced that results from the Phase 2 FLAVOR trial of CYR-064 will open the General Session at the...
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac DiseaseOctober 8, 2026, 7:00 AM CET
- Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for SchizophreniaAd Hoc Announcement Pursuant to Art. 53 LR
- The Rosen Law Firm PAROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a...
- AusperBio Therapeutics Inc.AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026Two abstracts on long-term follow-up data of AHB-137 treatment for chronic hepatitis B have been selected for late-breaking oral presentations at The Liver Meeting® 2026. — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together,...
- WuXi AppTecWuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for SustainabilityWuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for the third consecutive year, reflecting the Company's consistent commitment to...
- SEVER LIFE SCIENCES B.V. WIRD ÜBER IHRE TOCHTERGESELLSCHAFT NORDIC PHARMA, INC. PATIENTENDATEN UND DIE ERGEBNISSE EINER STUDIE ZUR PATIENTENERFAHRUNG MIT LACRIFILL® CANALICULAR GEL, EINER NEUARTIGEN THERAPIE ZUR KONTROLLE DER AUGENOBERFLÄCHE, IM RAHMEN DER TAGUNG DER AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2026 VORSTELLENDOYLESTOWN, Pennsylvania, 7. Oktober 2026 -- Nordic Pharma, Inc., eine Tochtergesellschaft von SEVER Life Sciences B.V., wird auf der Jahrestagung der American Academy of Ophthalmology vom 9. bis 12. Oktober in New Orleans, Louisiana, das LACRIFILL® Canalicular Gel vorstellen...
- Neo Dental Beverly Hills Beverly HillsNeo Dental Beverly Hills Introduces Neo-Essentialism: A Modern Approach to Clinical Decision-Making and a New Way to Think About Dentistry’s FutureAs dentistry moves toward regeneration, artificial intelligence, and biologic preservation, the Beverly Hills dentist behind the concept is asking whether progress may increasingly be defined by what clinicians can preserve, not only by what they can repair or replace.
- Glaukos CorporationGlaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in KeratoconusALISO VIEJO, Calif., October 07, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh
- Tennessee OncologyTennessee Oncology Physician Contributes to Landmark Longevity ResearchDr. Yanjun Ma helps uncover genetic and epigenetic clues to extraordinary longevity and cancer resistance in 194-year-old giant tortoise — Tennessee Oncology is contributing to groundbreaking research into one of biology's most enduring...